Miami
Thyroid Oncology Symposium
February 28-March 1, 2025
Molecular Diagnosis & Therapy
RAI Theranostics & Dosimetry
MIAMI
CANCER RESEARCH
CENTER
Miami Thyroid Oncology Symposium stands at the forefront of innovation in thyroid cancer care, serving as a premier platform for discussing groundbreaking advancements in the field. The 7th Miami Thyroid Oncology Symposium (MTOS) will be held on February 28 and March 1, 2025, Jointly sponsored by Miami Cancer Research Center (MCRC) and Society of Nuclear Medicine and Molecular Imaging (SNMMI). MTOS will bring together world-leading experts to discuss the transformative advances in the diagnosis and treatment of thyroid cancer, emphasizing the pivotal role of genomics, molecular diagnostics and therapy. The symposium bridges the genomic paradigm with the enduring importance of traditional approaches, including surgery and radioactive iodine (RAI) theranostics. The new transformed paradigm comes with new definitions such as mis-differentiated thyroid cancer and RAI-indifferent thyroid cancer
Symposium Overview
The symposium emphasizes a transformative shift in thyroid cancer management, integrating innovative molecular diagnostics and therapeutics with established surgical and nuclear approaches to redefine standards of care and improve patient outcomes. Attendees will gain critical insights into how molecular diagnostics navigate rational surgical decision-making and enhance the effectiveness of radioactive iodine (RAI) theranostics. Experts from various disciplines will guide thought-provoking lectures and dynamic panel discussions, addressing advancements in diagnostic and therapeutic modalities, including oncoprotein-targeted molecular therapies, immunotherapy, and solutions to common clinical challenges faced by practitioners. The interactive discussions will foster collaborative exchanges, focusing on the practical application of evolving strategies in clinical practice. Designed for meaningful engagement, the symposium's format ensures a rich learning experience. The first day will feature comprehensive lectures by globally recognized leaders in thyroid oncology, presenting cutting-edge research and clinical applications. On the second day, the format shifts to interactive panel discussions and Q&A sessions, encouraging active participation and exploration of practical implications from the latest findings and evidence-based recommendations.
Faculty-led sessions will critically examine the American Thyroid Association (ATA) guidelines in the context of recent scientific advancements, offering actionable insights for real-world application. Contributions from surgical oncologists, endocrinologists, pathologists, nuclear medicine specialists, and other experts will provide a multidisciplinary perspective that reflects the complexity of thyroid cancer care. Central to the discussions will be the critical role of radioactive iodine theranostics and redifferentiation strategies for treating RAI-indifferent thyroid cancers with special emphasis on dosimetry. The symposium will take place in person, with limited virtual access available for international participants. Bringing together pioneers in thyroid oncology, this event serves as an invaluable platform for clinicians, researchers, and healthcare professionals to stay at the forefront of thyroid cancer care while contributing to the evolution of the field during this exciting era of medical innovation.
Seza Gulec, MD, FACS, FACNM
Symposium Director
Seza Gulec
Seza Gulec, MD, FACS, FACNM, Symposium Director
Professor of Surgery and Nuclear Medicine
President of Medical Staff, HCA Florida, Aventura Hospital
CEO and Chairman of the Board, Miami Cancer Research Center
�Yuri E. Nikiforov, MD, PhD
Professor of Pathology
Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA
�Douglas Van Nostrand, MD, FACP, FACP, FACNP
Director, Nuclear Medicine Research, MedStar Health Research Institute
MedStar Washington Hospital Center
Professor of Medicine, Georgetown University
�Maria Cabanillas, MD
Professor, Endocrine Neoplasia & Hormonal Disorders,
The University of Texas MD Anderson Cancer Center, Houston, TX
�James A. Fagin, MD
Division Head, Subspecialty Medicine, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York, NY
�Laura Fugazzola, MD
Professor of Endocrinology
Department of Pathophysiology and Transplantation, University of Milan,
President of the European Thyroid Association
�Alan Ho, MD, PhD
Chief, Head and Neck Medical Oncology
Memorial Sloan Kettering Cancer Center, New York, NY
�Helen Nadel, MD
Clinical Professor, Pediatric Radiology, Director of Pediatric Nuclear Medicine including PET/MRI
Stanford Health Care; Stanford Medicine Children’s Health
SNMMI Immediate Past President
�Victor Bernet, MD, FACE, FACP
Director, Endocrinology, Diabetes and Metabolism Fellowship Program
Consultant, Division of Endocrinology, Mayo Clinic Florida
Professor, Mayo Clinic College of Medicine and Science, Former President, ATA
Prof. Andrew Scott
Department of Molecular Imaging and Therapy, Austin Health
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute
University of Melbourne, and La Trobe University, Melbourne, Australia�
Prof. Dr. Med. Luca Giovanella
Department of Nuclear Medicine and Thyroid Center - University Hospital of Zurich, Zurich, Switzerland
Department of Nuclear Medicine and Thyroid Center - Gruppo Ospedaliero Moncucco, Lugano, Switzerland Chair, Thyroid committee, EANM
�
Symposium Faculty
07:30: The New Terms and Concepts in Thyroid Oncology
Seza A Gulec
08:00: The Science, Craft and Art of Complex Thyroid Surgery
Aziz Aliyev
08:30: Active Surveillance for Management of Papillary Microcarcinoma: More than 30 years of experience
Akira Miyauchi
09:00: Molecular Diagnostics: Experience over 50,000 studies
Yuri Nikiforov
09:30: Discussion and Coffee Break
10:00: Molecular Therapies in Mis-differentiated, Poorly and Undifferentiated Thyroid Cancers Maria Cabanillas
10:30: Immune-mediated response of advanced thyroid cancers to MAPK inhibitors James Fagin
11:00: The Theranostic role for molecular testing in Bethesda 6 cytology and Surgical Pathology Yuri Nikiforov
11:30: Discussion and Luncheon Lectures
12:00: Radiofrequency Ablation of Thyroid Nodules and Cancer
Erivelto Volpi
12:30: PET/CT Molecular Imaging in Thyroid Cancer
Daryl Eber
13:00: RAI Refractory Thyroid Cancer
Douglas VanNostrand
13:30: Redifferentiating mis-differentiated thyroid cancers: MD Anderson Experience Maria Cabanillas
14: 00: Redifferentiation Modulating ERK output and Beyond, MSKCC Experience Alan Ho
14:30: The Key Role for Dosimetry for RAI treatment Response Reporting Seza A Gulec
15:00: Discussion and Coffee Break
15:30: Australian Experience with Redifferentiation therapy
A. Scott
16:00: RAI Radio-safety and Efficacy in Pediatric Patients
I-131 MIBG and I-131 NaI Experiences:
Helen Nadel
16:30: Progress in Nuclear Theranostics, Invitation to MARS SHOT Event Richard Wahl
17:00: Discussion
Program at a Glance
LECTURES
07:30: The Journey of Thyroidology
Cristina Benites
Young Scholar Award
08:00: Bridging Molecular Oncology to Clinical Oncology
Seza Gulec
08:30: Modulation of Oncophysiology through ERK signaling
Alan Ho
09:00: Impact of clonal hematopoiesis on the biology and
response to therapy of thyroid cancer
James Fagin
09:30: Discussion and Coffee Break
10:00: The position and Pulse of ETA in the New Genomics-guided Management Paradigm Laura Fugazzola
10:30: The position and Pulse of EANM in the New Genomics-guided Management Paradigm Luca Giovanella
11:00: The position and Pulse of SNMMI in the New Genomics-guided RAI Theranostics Douglas Van Nostrand
11:30 Exploring the Utility of Thyroid Cancer-related Genomic-Guided Management Strategies Victor Bernet
12:00: Discussion and Luncheon Lectures
12:00: Theranostics 2025: Thyroid and Beyond
Richard Baum
Science behind GLP-1 and Thyroid-associated Concerns
David Filippi
13:00: The New York (MSKCC) Protocol
Pat Zanzonico
13:30: The Miami (MCRC) Protocol
Andrew Prideaux
14: 00: The Australian Protocol
Dale Bailey
15:00: Discussion and Coffee Break
15:30-17:30
Case Presentations: Seza Gulec
A Clash of Guidelines
Inter-societal Consensus and Concessions
Clinical Trials Solutions
Program at a Glance
LECTURES
Seza Gulec, MD, FACS, FACNM,
Professor of Surgery and Nuclear Medicine
CEO and Chairman of the Board, Miami Cancer Research Center
President of Medical Staff, HCA Florida, Aventura Hospital
Yuri E. Nikiforov, MD, PhD
Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA
Douglas Van Nostrand, MD, FACP, FACNP
Professor of Medicine at Georgetown University Medical Center in Washington, DC
Director of Nuclear Medicine at MedStar Health Research Institute
Jean-Luc C. Urbain, MD, PhD, FASNC
Professor of Radiology/Nuclear Medicine and Medicine
President-elect of the Society of Nuclear Medicine and Molecular Imaging
MTOS Committees
STEERING COMMITTEE
Dahlia Mohammed, MPH
Vice President of Operations & Education Innovation, Miami Cancer Research Center, Miami, FL
Symposium Coordinator
Sharon Jenkins, EdD
Senior Director of Development and Marketing, SNMMI, Reston, VA
SNMMI-MCRC Liaison
Paul Perales-Villarroel, MD
Chief Operating Officer, Miami Cancer Research Center, Miami, FL
Symposium Coordinator
Cristina Benitez
Vice President of R&D and Informatics, Miami Cancer Research Center, Miami, FL
Symposium Coordinator
ORGANIZING COMMITTEE
In-Person Attendance
Categories:
General Admission (Physicians and Scientists): $225
Nurses and Midlevel Providers: $100
Students and Physicians in Training: $75
Miami Thyroid Oncology Consortium Members: Exclusive Rates
Why attend in person?
Attending in person adds a special touch to the experience. You’ll get to connect directly with leading professors, take part in engaging discussions and debates, and join unique special events that bring the program to life. Plus, you’ll enjoy complimentary food and drinks to keep you fueled throughout the day.
And with discounted registration fees, it’s an affordable way to make the most of everything this event has to offer. Join us in-person to connect, learn, and make this event truly memorable.
Virtual Attendance
$450 All Categories
As an added perk, virtual attendees also receive digital access to the program materials, so you can revisit anything you want at your own pace.
MTOS is organized by Miami Cancer Research Center (MCRC), a scientific and charitable organization that performs and supports cancer research, organizes educational events and provides support for cancer care at institutional and individual levels. The mission of the MCRC is to take part in the global fight against cancer through research, education and patient care support. The symposium is endorsed and supported by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Dade County Medical Association and Miami Cancer Research Center. The Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians. DCMA designates this educational activity for a maximum 0f 16 AMA PRA Category 1 credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
REGISTRATION
SYMPOSIUM ORGANIZATION
CONTINUOUS MEDICAL EDUCATION CREDITS
CONFERENCE VENUE
Roz & Cal Kovens Conference Center at FIU’s Biscayne Campus
The MTOS 2025 is a hybrid event. Symposium will be held at the Roz & Cal Kovens Conference Center at the FIU’s Biscayne Campus. 3000 NE 151st Street, North Miami Beach, FL, 33181. The event will be live broadcasted for national and international audience. The core faculty will be attending in person. The symposium welcomes all professionals involved or interested in the care of patients with thyroid nodules or cancer. It is also open to public who are keen to learn the state of the art technology in thyroid cancer diagnosis and treatment. The symposium venue is close to many hotels with different packages and offers. The headquarter hotel is “Marenas Beach Resort” in Sunny Isles Beach. Symposium registration fee is $450 which includes parking, food and beverages.
SYMPOSIUM SUPPORT
This symposium is supported by commercial sponsorship by the following industry partners
MIAMI
CANCER RESEARCH
CENTER